Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress


- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -

Read more here:
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Related Posts